Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Resolution Crystallization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN115850115B reveals high-purity Ruxolitinib intermediate synthesis. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Advanced purification process for tenofovir prodrug ensuring high purity. Cost-effective supply chain solutions for pharmaceutical intermediates. Reliable manufacturing partner for global pharmaceutical companies seeking scalable synthesis routes.
Patent CN111763150B reveals a novel L-glutamic acid resolution method for high-purity sertraline, offering significant cost reduction and supply chain reliability for global buyers.
Patent CN107674072B reveals a scalable resolution method for dihydropyrimidine intermediates using L-tartaric acid, offering superior optical purity and cost-effective manufacturing for pharmaceutical supply chains.
Patent CN1915974A details NMP-based chiral resolution for high-purity Amlodipine. Offers significant cost reduction and supply chain reliability for API manufacturing partners.
Novel resolution process enhances purity and supply continuity for D-Calcium Pantothenate manufacturing reducing costs significantly for global buyers.
Novel resolution method using ethyl acetate and ethanol mixtures ensures high optical purity and yield for scalable antidepressant intermediate production.
Patent CN111056939A reveals a novel recrystallization method for (1R,3S)-3-aminocyclopentanol, offering high optical purity and yield for Bictegravir synthesis.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis. Our CDMO expertise delivers >99% ee intermediates with 92% yield, reducing impurity risks for oncology drug development.